coverage from
i
What that date means
Coverage begins on 2026-08-11, which is when this archive started holding
Federal Register issues — not when the agency started publishing.
Anything earlier is absent from this page, and its absence is not evidence.
The Drug Enforcement Administration temporarily scheduled O-desmethyltramadol as a Schedule I controlled substance effective immediately.
The Drug Enforcement Administration published a notice on exempt chemical preparations under the Controlled Substances Act for applications received between March and June 2026.
The Drug Enforcement Administration published twelve notices regarding controlled substance registration applications and one decision and order.
The DEA temporarily placed mitragynine pseudoindoxyl, MGM-15, and MGM-16 in Schedule I of the Controlled Substances Act.
The Drug Enforcement Administration placed cipepofol in Schedule IV and temporarily placed four synthetic opioid analogues in Schedule I of the Controlled Substances Act.
The Drug Enforcement Administration published three decision and order notices regarding Atlantic Treatment Center, Thomas Earley, and Leila Kump.
The Drug Enforcement Administration published seven notices on controlled substance registrations and practitioner actions.
The Drug Enforcement Administration published four Decision and Order notices regarding Emran Mohammad, Joseph John Stubbers III, Cheryl White, and Craig Cohen.
The Drug Enforcement Administration published notices regarding controlled substance importer and bulk manufacturer applications from Irvine Labs, Inc. and Cambrex High Point, Inc.
The Drug Enforcement Administration placed diphenidine in schedule I of the Controlled Substances Act, effective October 21, 2026.
The Drug Enforcement Administration proposed placing five tryptamine hallucinogens into Schedule I of the Controlled Substances Act.
The Drug Enforcement Administration published notices of five applications for controlled substance manufacturer and importer registrations.
The Drug Enforcement Administration published five decision and order notices regarding Angela Turner-Brown, JT Medical LLC, Christopher Nadorff, Jorge Figueroa, and Johann Farley.
The Drug Enforcement Administration published four notices on October 7, 2026, including decision and orders for Medpharm Research, Wellwise Pharmacy, and Arenbii Pharmacy.
The DEA published two rules removing exemption status for inactive butalbital products and correcting Schedule I placement language for O-desmethyltramadol, and three notices of decisions and orders.
The DEA published two proposed rules to schedule hydroxymitragynine-related substances and one notice regarding a practitioner decision.
The Drug Enforcement Administration published eleven notices regarding applications for controlled substance importer and bulk manufacturer registrations and one decision and order.
Ask an assistant instead
Everything on this page is also a tool call. Add
mcp.downstream.sh as an MCP server in Claude, ChatGPT, or any client that speaks the
protocol — no key, no account — then paste this:
Using the Downstream MCP server at mcp.downstream.sh, call whats_new_since with agency "Drug Enforcement Administration" since 2026-08-11, then tell me what this agency has been working on and which of its deadlines are still open.
Reaches whats_new_since. The response carries its own citations
and states what it is missing — including which dates it has no record for.